All patients
Age < 65y (younger) Age > 65y Asian type cancer location (gastric) cancer location (gastro-esophageal) ECOG 0 ECOG 1 Gender, female Gender, male previous gastrectomy previous gastrectomy NO
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mGC or mGEJC - L1 - PDL1 positive, pembrolizumab based treatment vs. Standard of Care (SoC), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.91 [0.75; 1.11]
KEYNOTE-062 (P vs C ; CPS>10), 2020 0.69 [0.49; 0.97]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.85 [0.70; 1.03]
KEYNOTE-062 (PC vs C ; CPS>10), 2020 0.85 [0.62; 1.17]
0.85 [0.75 ; 0.96 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (P vs C ; CPS>10), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>10), 2020 4 0% 1,384 low not evaluable progression or deaths (PFS)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 1.66 [1.37; 2.01]
KEYNOTE-062 (P vs C ; CPS>10), 2020 1.10 [0.80; 1.52]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.84 [0.70; 1.01]
KEYNOTE-062 (PC vs C ; CPS>10), 2020 0.73 [0.53; 1.00]
1.04 [0.70 ; 1.54 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (P vs C ; CPS>10), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>10), 2020 4 91% 1,384 low not evaluable objective responses (ORR)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.29 [0.19; 0.45]
KEYNOTE-062 (P vs C ; CPS>10), 2020 0.55 [0.29; 1.04]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.60 [1.12; 2.28]
KEYNOTE-062 (PC vs C ; CPS>10), 2020 1.82 [1.02; 3.26]
0.83 [0.33 ; 2.08 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (P vs C ; CPS>10), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>10), 2020 4 93% 1,384 low not evaluable AE (any grade)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.34 [0.11; 1.06]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.68 [0.19; 2.43]
0.46 [0.20 ; 1.08 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable AE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.09 [0.06; 0.14]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.16 [0.79; 1.71]
0.32 [0.03 ; 4.02 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 99% 992 low not evaluable AE leading to death (grade 5)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.19; 4.80]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.64 [0.39; 6.94]
1.29 [0.44 ; 3.78 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 low not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.19 [0.09; 0.38]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.73 [1.13; 2.66]
0.58 [0.07 ; 5.15 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 96% 992 low not evaluable TRAE (any grade)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.11 [0.06; 0.18]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.40 [0.70; 2.80]
0.38 [0.03 ; 4.77 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 97% 992 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.97 [0.06 ; 15.52 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.10 [0.03; 0.27]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.81 [0.48; 1.37]
0.29 [0.04 ; 2.39 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 92% 992 low not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.09 [0.01; 0.73]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.87 [0.35; 2.19]
0.35 [0.04 ; 3.02 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 74% 992 low not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.06; 15.44]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.49 [0.02; 14.58]
0.73 [0.09 ; 6.29 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.97 [0.06 ; 15.52 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.16 [0.05; 0.55]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.61 [0.28; 1.34]
0.34 [0.09 ; 1.27 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 69% 992 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.20 [0.06; 0.69]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.83 [0.38; 1.83]
0.44 [0.11 ; 1.78 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 72% 992 low not evaluable Dizziness TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.48 [0.02; 14.35]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.06; 15.69]
0.73 [0.09 ; 6.31 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 low not evaluable Dry skin TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.97 [0.06 ; 15.52 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Dysgeusia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.97 [0.06 ; 15.52 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.06 [0.01; 0.50]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.35 [0.66; 2.76]
0.35 [0.02 ; 6.67 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 87% 992 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 1.92 [0.06; 57.64]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.96 [0.07; 58.57]
1.94 [0.18 ; 21.47 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.48 [0.02; 14.35]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 5.98 [0.71; 50.01]
2.43 [0.23 ; 25.98 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 34% 992 low not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.03 [0.00; 0.51]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.70 [0.32; 1.56]
0.20 [0.01 ; 4.07 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 77% 992 low not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.05 [0.01; 0.37]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.03 [0.53; 2.02]
0.26 [0.01 ; 5.10 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 87% 992 low not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.01 [0.00; 0.08]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.87 [0.58; 1.30]
0.08 [0.00 ; 12.29 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 92% 992 low not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.06 [0.00; 1.02]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.49 [0.60; 3.70]
0.40 [0.02 ; 8.98 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 78% 992 low not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.24 [0.01; 5.32]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.97 [0.36; 10.84]
1.04 [0.16 ; 6.94 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 27% 992 low not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 5.91 [0.29; 118.71]
5.91 [0.29 ; 118.71 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.97 [0.06 ; 15.52 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.96 [0.07; 58.57]
1.44 [0.11 ; 18.83 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 low not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.05 [0.00; 0.89]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.20 [0.49; 2.95]
0.34 [0.02 ; 6.97 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 77% 992 low not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.08 [0.00; 1.41]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.14 [0.38; 3.45]
0.42 [0.03 ; 5.35 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 65% 992 low not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.03 [0.00; 0.55]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.83 [0.38; 1.83]
0.22 [0.01 ; 5.00 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 79% 992 low not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.48 [0.02; 14.35]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.96 [0.18; 21.75]
1.22 [0.17 ; 8.73 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 low not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 17:40 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 184
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561